9.82  -0.2 (-2%)		08-13 16:00
Open: 10.07 High: 10.07 Volume: 46,450		Pre. Close: 10.02 Low: 9.8 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	12.49	1-year :	14.59
Resists	First :	10.69	Second :	12.49
Pivot price	9.83
Supports	First :	9.09	Second :	8.1
MAs	MA(5) :	9.98	MA(20) :	9.63
	MA(100) :	7.6	MA(250) :	7.48
MACD	MACD :	0.4	Signal :	0.5
%K %D	K(14,3) :	60.6	D(3) :	66.3
RSI	RSI(14): 59.5
52-week	High :	13.39	Low :	4.84

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MSLE ] has closed above bottom band by 48.2%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	10.09 - 10.15	10.15 - 10.21
Low:	9.64 - 9.7	9.7 - 9.77
Close:	9.7 - 9.81	9.81 - 9.93

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Thu, 13 Aug 2026
Satellos Bioscience: Q2 Earnings Snapshot - Yahoo Finance

Thu, 13 Aug 2026
Satellos Bioscience: Q2 Earnings Snapshot - KVUE

Thu, 16 Jul 2026
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: EPS Misses Estimates as Development Costs Continue - dars.gov.et

Fri, 10 Jul 2026
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView

Mon, 29 Jun 2026
Satellos wins FDA Fast Track for Duchenne drug SAT-3247 - Stock Titan

Thu, 25 Jun 2026
Satellos to Present Clinical Program Updates at ICNMD 2026 - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	21 (M)
Shares Float	18 (M)
Held by Insiders	6.4 (%)
Held by Institutions	50.6 (%)
Shares Short	83 (K)
Shares Short P.Month	70 (K)

EPS	-1.79
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.39
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-31.4 %
Return on Equity (ttm)	-50.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.21
Sales Per Share	0
EBITDA (p.s.)	-1.45
Qtrly Earnings Growth	0 %
Operating Cash Flow	-26 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-5.49
PEG Ratio	0
Price to Book value	2.89
Price to Sales	0
Price to Cash Flow	-7.93

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.